Form D · Biotechnology
Inso Biosciences Inc.
Ithaca, NY · CIK 0001906426
Offering snapshot reported Apr 10, 2026 · SEC filing
- Reported sold
- $750K Offering amount: $3M
- Investors reported
- 9 Form D · investor count
- Minimum accepted
- $0 Reported outside-investor minimum
- First sale
- Mar 3, 2026 As reported in this filing
What changed?
Latest filing versus its linked predecessor, where available.
No comparable changes in the displayed metrics.
Filing history
Scroll to see all columns →
| Filed | Filing type | Reported sold | Change vs linked filing | Investors | Source |
|---|---|---|---|---|---|
| Apr 10, 2026 | Initial | $750,000 | No comparison | 9 | SEC filing |
| Feb 25, 2022 | Initial | $1,775,000 | No comparison | 4 | SEC filing |
Offering details
- Securities
- Debt, Option to acquire, Security to be acquired, Other
- Exemptions
- 06b
- Duration over one year
- No
- Business combination
- No
- Sales commissions
- $0
- Finders' fees
- $0
- Form D file number
- 021-579922
Convertible promissory notes convertible into equity securities of the Issuer and the equity securities to be acquired upon such conversion.
Source: Form D, filed Apr 10, 2026. Minimum accepted may differ from a standard advertised minimum.
Fund connections
No confirmed ADV fund connection is available for this issuer.
People & organizations
Current and past Form D appearances. These existing records do not establish a person's current role or uniquely identify them across issuers.
| Name | Reported role |
|---|---|
| Adam Bisogni | Director |
| Harvey Chen Tian | Director, Executive |
Issuer details
Industry: Biotechnology (See others in industry)
Address:
237 Tower Road, Room 410 Weill Hall Mcgovern Center
Ithaca, NY, 14853
Ithaca, NY, 14853